NeuroMetrix (NASDAQ:NURO) Research Coverage Started at StockNews.com

Equities researchers at StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NURO) in a report issued on Friday. The firm set a “sell” rating on the medical device company’s stock.

NeuroMetrix Stock Performance

NURO stock opened at $4.44 on Friday. The business has a fifty day simple moving average of $3.89 and a 200-day simple moving average of $3.77. NeuroMetrix has a 52 week low of $2.70 and a 52 week high of $11.55.

NeuroMetrix (NASDAQ:NURO) last released its quarterly earnings data on Thursday, February 22nd. The medical device company reported ($1.43) EPS for the quarter. The firm had revenue of $1.32 million for the quarter. NeuroMetrix had a negative return on equity of 31.31% and a negative net margin of 110.64%.

Institutional Trading of NeuroMetrix

A hedge fund recently bought a new stake in NeuroMetrix stock. Cerity Partners LLC purchased a new stake in NeuroMetrix, Inc. (NASDAQ:NURO) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 30,000 shares of the medical device company’s stock, valued at approximately $108,000. Cerity Partners LLC owned approximately 2.80% of NeuroMetrix at the end of the most recent quarter. Institutional investors and hedge funds own 19.40% of the company’s stock.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.